History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis

References

• Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:23–35.
   PubMedGoogle Scholar
• Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of febrile neutropenia hospitalization (FNH) associated with chemotherapy. Paper presented at 2003 ASCO Annual Meeting, Chicago, IL, 31 May–3 June 2003.
   Google Scholar
• Bhana N. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. Curr Opin Oncol 2007;19:328–335.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol 2007;19:299–307.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402–407.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129–146.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer 2007;15:477–482.
   PubMed Web of Science ®Google Scholar
• Ellis GK, Livingston RB, Gralow JR, et al. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002;20:3637–3643.
   PubMed Web of Science ®Google Scholar
• Baskaran ND, Gan GG, Adeeba K. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 2008;87:563–569.
   PubMed Web of Science ®Google Scholar
• Lopez-Pousa A, Rifa J, Casas de Tejerina A, et al. Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care (Engl) 2010;19:648–655.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.
   PubMed Web of Science ®Google Scholar
• Koebnick C, Langer-Gould A, Gould MK, et al. Do the sociodemographic characteristics of members of a large, integrated health care system represent the population of interest? Perm J 2012;16:37–41.
   PubMedGoogle Scholar
• National Cancer Institute. SEER quality improvement. Available from: http://seer.cancer.gov/qi/index.html.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–383.
   PubMedGoogle Scholar
• NCCN Clinical Practice Guidelines in Oncology. Myeloid growth factors, v1.2012. Available from: www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Feldman S, Stein D, Amrute S, et al. Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol 2001;101:201–210.
   PubMed Web of Science ®Google Scholar
• Wickramasinghe SN, Beatty C, Shiels S, et al. Ultrastructure of the bone marrow in HIV infection: evidence of dyshaemopoiesis and stromal cell damage. Clin Lab Haematol 1992;14:213–229.
   PubMedGoogle Scholar
• Widdifield J, Bernatsky S, Michael Paterson J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:353–361.
   PubMed Web of Science ®Google Scholar
• Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity. Endocr Rev 1993;14:107–120.
   PubMed Web of Science ®Google Scholar
• van Dartel SA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895–900.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258–2266.
   PubMed Web of Science ®Google Scholar
• Carroll J, Protani M, Walpole E, et al. Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Res Treat 2012;136:323–330.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004;22:648–657.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003;98:484–495.
   PubMed Web of Science ®Google Scholar